On July 16, 2026, Aditxt, Inc. entered into Amendment No. 2 to its Note Purchase Agreement with Ignite Proteomics LLC and existing investors. The amendment allows a new party to join as an investor, cancels one existing note, and issues two additional notes of equal principal amount. This transaction does not change the aggregate principal amount of the senior secured notes. The notes are secured by substantially all assets of Ignite and the equity held by Aditxt in Ignite. Aditxt, Inc. is a healthcare technology company focused on immune system monitoring and data analytics.
